- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03634540
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
May 2, 2023 updated by: Peloton Therapeutics, Inc.
A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC.
Belzutifan and cabozantinib will be administered orally once daily.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
118
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- USC Norris Comprehensive Cancer Center ( Site 0060)
-
Los Angeles, California, United States, 90048
- Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003)
-
-
Florida
-
Miami, Florida, United States, 33136
- Sylvester Comprehensive Cancer Center ( Site 0023)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Center ( Site 0006)
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute ( Site 0033)
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Tennessee Oncology, PLLC ( Site 0024)
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology, PLLC ( Site 0001)
-
-
Texas
-
Dallas, Texas, United States, 75246
- Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 0010)
-
-
Washington
-
Seattle, Washington, United States, 98104
- Swedish Cancer Institute ( Site 0018)
-
Seattle, Washington, United States, 98109
- Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0035)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Has locally advanced or metastatic RCC with predominantly clear cell subtype
- Has at least one measurable lesion as defined by RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Has adequate organ function defined as follows:
- Absolute neutrophil count ≥ 1,000/µL, hemoglobin level ≥ 10 g/dL and platelet count ≥ 100,000/µL without transfusion or growth factor support within 2 weeks prior to obtaining the hematology values at screening;
- Serum creatinine level ≤ 2.0 × upper limit of normal (ULN)
- Transaminase levels (AST/ALT) ≤ 3.0 × upper limit of normal (ULN); total bilirubin (TBILI) ≤ 1.5 mg/dL in the absence of Gilbert's disease *Cohort 1: Participants must not have received prior systemic therapy for advanced or metastatic ccRCC
- Cohort 2: Participants must have received prior immunotherapy and no more than two prior treatments for advanced or metastatic ccRCC
Exclusion Criteria:
- Has received prior treatment with belzutifan or other HIF2α inhibitors
- Has received prior treatment with cabozantinib
- Has had radiation therapy for bone metastases within two weeks of starting study drug
- Has a history of untreated brain metastases or history of leptomeningeal disease or spinal cord compression
- Has failed to recover from the reversible effects of prior anticancer therapy
- Has uncontrolled or poorly controlled hypertension
- Is receiving anticoagulant therapy
- Has had any major cardiovascular event within 6 months prior to study drug administration
- Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results
- Has had major surgery within 3 months before first study drug administration
- Has an active infection requiring systemic treatment
- Is participating in another therapeutic clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1)
Naïve participants will receive 120 mg belzutifan and 60 mg cabozantinib orally once daily (QD) at the same time.
|
Belzutifan tablets administered orally.
Other Names:
Cabozantinib tablets administered orally.
Other Names:
|
Experimental: Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2)
Participants who have received prior immunotherapy will receive 120 mg belzutifan and 60 mg cabozantinib orally QD at the same time.
|
Belzutifan tablets administered orally.
Other Names:
Cabozantinib tablets administered orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to approximately 2 years
|
ORR is defined as the percentage of participants with a best confirmed response of Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) as determined by the investigator using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
|
Up to approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: Up to approximately 2 years
|
PFS is defined as the interval from the start of study treatment until the earlier of the first documentation of disease progression determined by RECIST 1.1 or death from any cause.
|
Up to approximately 2 years
|
Duration of Response (DOR)
Time Frame: Up to approximately 2 years
|
DOR is defined as the interval from the first documentation of response, as determined by RECIST 1.1, to the earlier of the first documentation of disease progression or death from any cause, and calculated for participants with a best confirmed response of CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions).
|
Up to approximately 2 years
|
Time to Response (TTR)
Time Frame: Up to approximately 2 years
|
TTR is defined as the interval from the start of study treatment to the first documentation of a response, as determined by RECIST 1.1, and calculated for participants with a best confirmed response of CR or PR.
|
Up to approximately 2 years
|
Overall Survival (OS)
Time Frame: Up to approximately 2 years
|
OS is defined as the interval from the start of treatment to the death of the participant from any cause.
|
Up to approximately 2 years
|
Number of participants experiencing an Adverse Event (AE)
Time Frame: Up to approximately 2 years
|
An AE is defined as any untoward medical occurrence in a participant regardless of its causal relationship to study treatment.
An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not it is considered to be study drug related.
Included in this definition are any newly occurring events and any previous condition that has increased in severity or frequency since the administration of study drug.
|
Up to approximately 2 years
|
Number of participants discontinuing study treatment due to an Adverse Event (AE)
Time Frame: Up to approximately 2 years
|
An AE is defined as any untoward medical occurrence in a participant regardless of its causal relationship to study treatment.
An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not it is considered to be study drug related.
Included in this definition are any newly occurring events and any previous condition that has increased in severity or frequency since the administration of study drug.
|
Up to approximately 2 years
|
Belzutifan Plasma Concentration
Time Frame: Weeks 1 and 4: pre-dose, 2 and 6 hours post-dose
|
Blood samples for the determination of belzutifan concentration will be collected at pre-specified timepoints before and after treatment administration.
|
Weeks 1 and 4: pre-dose, 2 and 6 hours post-dose
|
Belzutifan Metabolite Plasma Concentration
Time Frame: Weeks 1 and 4: pre-dose, 2 and 6 hours post-dose
|
Blood samples for the determination of belzutifan metabolite concentration will be collected at pre-specified timepoints before and after treatment administration.
|
Weeks 1 and 4: pre-dose, 2 and 6 hours post-dose
|
Cabozantinib Plasma Concentration
Time Frame: Weeks 1 and 4: pre-dose, 2 and 6 hours post-dose
|
Blood samples for the determination of cabozantinib concentration will be collected at pre-specified timepoints before and after treatment administration.
|
Weeks 1 and 4: pre-dose, 2 and 6 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 27, 2018
Primary Completion (Anticipated)
August 31, 2025
Study Completion (Anticipated)
August 31, 2025
Study Registration Dates
First Submitted
August 3, 2018
First Submitted That Met QC Criteria
August 14, 2018
First Posted (Actual)
August 16, 2018
Study Record Updates
Last Update Posted (Estimate)
May 4, 2023
Last Update Submitted That Met QC Criteria
May 2, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6482-003
- PT2977-201 (Other Identifier: Peloton)
- MK-6482-003 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Cancer
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnKidney/Urinary Cancer
-
PfizerCompletedKidney Cancer | Kidney Neoplasms | Renal Cell Carcinoma | Renal Cancer | Renal Cell Cancer | Cancer of the Kidney | Cancer of KidneyFinland
-
Tianjin Medical University Second HospitalRecruiting
-
Tianjin Medical University Second HospitalRecruiting
-
Cedars-Sinai Medical CenterRecruitingProstate Cancer Stage II | Prostate Cancer Stage I | Bladder Cancer Stage II | Kidney Cancer Stage IUnited States
-
Dana-Farber Cancer InstituteCompletedKidney Cancer | Prostate Cancer | Genitourinary CancerUnited States
-
Intuitive SurgicalCompleted
-
University of Texas Southwestern Medical CenterCompletedKidney Cancer | Kidney Cancer Metastatic | Kidney Cancer, Stage IVUnited States
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
Clinical Trials on Belzutifan
-
Peloton Therapeutics, Inc.CompletedHealthyUnited States
-
Merck Sharp & Dohme LLCActive, not recruitingEnd Stage Renal Disease | Renal ImpairmentUnited States
-
Merck Sharp & Dohme LLCRecruitingVon Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated CancersCanada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
-
Merck Sharp & Dohme LLCActive, not recruitingCarcinoma, Renal CellUnited States, Australia, Belgium, Greece, Ireland, Israel, Netherlands, Russian Federation, United Kingdom
-
Merck Sharp & Dohme LLCCompletedModerate Hepatic ImpairmentUnited States
-
Merck Sharp & Dohme LLCActive, not recruitingCarcinoma, Renal CellUnited States
-
Peloton Therapeutics, Inc., a subsidiary of Merck...Active, not recruitingVHL - Von Hippel-Lindau Syndrome | VHL Gene Mutation | VHL Syndrome | VHL Gene Inactivation | VHL-Associated Renal Cell Carcinoma | VHL-Associated Clear Cell Renal Cell CarcinomaUnited States, Denmark, United Kingdom, France
-
Peloton Therapeutics, Inc.Active, not recruitingA Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...
-
HiberCell, Inc.Merck Sharp & Dohme LLCRecruitingRenal Cell CarcinomaUnited States
-
Dana-Farber Cancer InstituteEli Lilly and CompanyActive, not recruiting